LLY vs PPBT

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Purple Biotech targets high-unmet-need oncology markets with a promising diversified pipeline, including the novel CAPTN-3 tri-specific antibody platform progressing towards IND (Q4 2026) and two Phase 2 assets (CM24, NT219) positioned for partnerships, indicating substantial TAM and significant 10x potential upon clinical success. A crucial positive development since the last analysis is the exte...